SCHEMBL3609897

SCHEMBL3609897

Cc1cc(N(Cc2ccc(C(F)(F)F)cc2)C(=O)OC(C)(C)C)cc(C)c1N

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 1/20 0.39
PDK4 Q16654 1/20 0.39
PTGDR2 Q9Y5Y4 3/20 0.38
CYP2C8 P10632 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
KCNQ2 O43526 3/20 0.38
KCNQ3 O43525 2/20 0.38
PDK1 Q15118 1/20 0.37
KCNQ4 P56696 1/20 0.37
KCNQ5 Q9NR82 1/20 0.37
HDAC1 Q13547 2/20 0.37
HDAC6 Q9UBN7 1/20 0.37
HDAC5 Q9UQL6 1/20 0.37
LSS P48449 1/20 0.37
LTB4R2 Q9NPC1 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC2 Q92769 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2069707 0.89 PDK2 (0.41) PDK2PDK4PTGDR2PDK1HDAC1
SCHEMBL27706496 0.85 PDK2 (0.42) PDK2PDK4PTGDR2CYP2C8CYP2C9
SCHEMBL3604936 0.84 MMP1 (0.37) PDK2PDK4PTGDR2CYP2C8CYP2C9
SCHEMBL2070045 0.81 CYP19A1 (0.43) PDK2PDK4PTGDR2PDK1HDAC1
SCHEMBL12252112 0.78 PDK2 (0.41) PDK2PDK4PDK1HDAC6LSS
SCHEMBL25287503 0.78 RIPK1 (0.37) CYP2C8KCNQ2KCNQ4KCNQ5HDAC1
SCHEMBL24497425 0.77 ALDH1A1 (0.38) PDK2PDK4PDK1LSSLTB4R2
SCHEMBL24497370 0.76 LSS (0.35) PDK2PDK4PTGDR2PDK1HDAC6
SCHEMBL29648358 0.76 LSS (0.35) PDK2PDK4PTGDR2PDK1HDAC6
SCHEMBL5018764 0.76 LSS (0.44) HDAC1LSSMEN1KMT2AHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100063044-A1 SUBSTITUTED ANILINE DERIVATIVES H. LUNDBECK A/S (DK) 2010-03-11 US disclosed
US-7601870-B2 Such as Hexanoic acid (4-bromo-2,6-dimethyl-phenyl)-amide; potassium channel modulators; epilepsy H. LUNDBECK A/S (DK) 2009-10-13 US disclosed
EP-1791809-A1 SUBSTITUTED ANILINE DERIVATIVES H. LUNDBECK A/S (DK) 2007-06-06 EP disclosed
US-20060155121-A1 Substituted aniline derivatives H. LUNDBECK A/S (DK) 2006-07-13 US disclosed
WO-2006029623-A1 SUBSTITUTED ANILINE DERIVATIVES H. LUNDBECK A/S (DK) 2006-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063044-A1 SUBSTITUTED ANILINE DERIVATIVES NDUFS3, NAT1, PRMT3 PDK2 1466/4885PDK4 2196/4885PTGDR2 3163/4885
US-20060155121-A1 Substituted aniline derivatives UGT2B7, NAT1, CYP1A2 PDK2 922/4885PDK4 1952/4885PTGDR2 2880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.